Matching articles for "finerenone"

Drugs for Chronic Heart Failure

   
The Medical Letter on Drugs and Therapeutics • May 26, 2025;  (Issue 1729)
Pharmacologic management of chronic heart failure (HF) is primarily determined by the patient's left ventricular ejection fraction (LVEF) and severity of symptoms. Patients with chronic HF who have an LVEF...
Pharmacologic management of chronic heart failure (HF) is primarily determined by the patient's left ventricular ejection fraction (LVEF) and severity of symptoms. Patients with chronic HF who have an LVEF ≤40% are considered to have heart failure with reduced ejection fraction (HFrEF) and those with an LVEF ≥50% are considered to have heart failure with preserved ejection fraction (HFpEF). Patients with an LVEF of 41-49% have heart failure with mildly reduced or mid-range ejection fraction.
Med Lett Drugs Ther. 2025 May 26;67(1729):81-8 | Show Full IntroductionHide Full Introduction

Comparison Chart: Some Drugs for HFrEF

   
The Medical Letter on Drugs and Therapeutics • May 26, 2025;  (Issue 1729)
...
View the Comparison Chart: Some Drugs for HFrEF
Med Lett Drugs Ther. 2025 May 26;67(1729):e1-15 | Show Full IntroductionHide Full Introduction

In Brief: Finerenone (Kerendia) for Diabetic Kidney Disease

   
The Medical Letter on Drugs and Therapeutics • January 23, 2023;  (Issue 1668)
Recently published guidelines from the American Diabetes Association (ADA) and the Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group recommend addition of the oral...
Recently published guidelines from the American Diabetes Association (ADA) and the Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group recommend addition of the oral nonsteroidal mineralocorticoid receptor antagonist (MRA) finerenone (Kerendia) to standard treatment in patients with type 2 diabetes and chronic kidney disease (CKD).
Med Lett Drugs Ther. 2023 Jan 23;65(1668):15-6 | Show Full IntroductionHide Full Introduction

Finerenone (Kerendia) for Chronic Kidney Disease

   
The Medical Letter on Drugs and Therapeutics • August 23, 2021;  (Issue 1631)
Finerenone (Kerendia – Bayer), an oral nonsteroidal mineralocorticoid receptor antagonist (MRA), has been approved by the FDA to reduce the risk of sustained eGFR decline, end-stage renal...
Finerenone (Kerendia – Bayer), an oral nonsteroidal mineralocorticoid receptor antagonist (MRA), has been approved by the FDA to reduce the risk of sustained eGFR decline, end-stage renal disease, nonfatal MI, hospitalization for heart failure (HF), and cardiovascular death in adults with chronic kidney disease (CKD) associated with type 2 diabetes. It is the first nonsteroidal MRA to be approved in the US.
Med Lett Drugs Ther. 2021 Aug 23;63(1631):131-2 | Show Full IntroductionHide Full Introduction